Scarica l'app Stockscreener
73.80
7.48%
-5.97
Dopo l'orario di chiusura:
73.13
-0.67
-0.91%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$79.77
Aprire:
$77.34
Volume 24 ore:
6.55M
Relative Volume:
0.90
Capitalizzazione di mercato:
$29.28B
Reddito:
$2.23B
Utile/perdita netta:
$-3.19B
Rapporto P/E:
-9.0594
EPS:
-8.1462
Flusso di cassa netto:
$-1.60B
1 W Prestazione:
+1.79%
1M Prestazione:
+55.04%
6M Prestazione:
+117.96%
1 anno Prestazione:
+126.80%
Intervallo 1D:
$73.34
$78.30
Intervallo di 1 settimana:
$73.34
$85.60
Portata 52W:
$22.28
$85.60
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
73.80 | 31.65B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
498.43 | 132.55B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
662.88 | 70.90B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
915.30 | 57.21B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.50 | 42.94B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.77 | 40.49B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Equal Weight |
| 2026-01-07 | Ripresa | UBS | Neutral |
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna (MRNA) Settles Vaccine Patent Case With $950 Million Upfront Payment - simplywall.st
MRNA Maintained by Morgan Stanley -- Price Target Raised to $39 - GuruFocus
MRNA Stock Heads to $60 as Investors Liquidate after New Moderna Board Appointment Announcement - FXLeaders
Moderna (MRNA) Welcomes Michael McDonnell to Board of Directors - GuruFocus
Why Moderna Stock Is the S&P 500’s Big Loser Today - Barron's
Moderna appoints Michael McDonnell to board; shares retreat from 52-week high - Seeking Alpha
Moderna (MRNA) Appoints Michael McDonnell to Board of Directors - GuruFocus
Moderna Inc outlines its next phase. MRNA pivots beyond Covid vaccines - AD HOC NEWS
Moderna Inc. focuses on mRNA pipeline as investors watch Nasdaq trading - AD HOC NEWS
Moderna adds former Biogen CFO to board of directors By Investing.com - Investing.com Canada
Former Biogen CFO Michael McDonnell joins Moderna (NASDAQ: MRNA) board and Audit Committee - Stock Titan
Moderna Appoints Michael McDonnell to Board of Directors - Eagle-Tribune
Moderna adds former Biogen CFO Michael McDonnell to its board - Stock Titan
Bank of America Securities Reaffirms Their Sell Rating on Moderna (MRNA) - The Globe and Mail
The Moderna Omicron XBB.1.5 vaccine. Updated booster targets current variants - AD HOC NEWS
Meitav Investment House Ltd. Sells 16,067 Shares of Moderna, Inc. $MRNA - MarketBeat
Morgan Stanley Adjusts Price Target Moderna to $39 From $33, Maintains Equalweight Rating - marketscreener.com
Hsbc Holdings PLC Sells 107,077 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna Stock Surges 37%, With A 6-Day Winning Spree - Trefis
Moderna Stock On Fire: Up 37% With 6-Day Winning Streak - Trefis
Form 4 Moderna Inc For: 7 July By Investing.com - Investing.com Canada
Moderna (MRNA) Chief Commercial Officer awarded RSUs and stock options - Stock Titan
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week - Yahoo Finance
MRNA Maintained by RBC Capital -- Price Target Raised to $45 - GuruFocus
MRNA Maintained by B of A Securities -- Price Target Raised to $38 - GuruFocus
Strs Ohio Acquires 68,887 Shares of Moderna, Inc. $MRNA - MarketBeat
RBC Capital Adjusts Moderna Price Target to $45 From $38, Maintains Sector Perform Rating - marketscreener.com
Moderna Stock Is Soaring. Is It Too Late to Buy? - The Motley Fool
Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Moderna (MRNA) CFO reports RSU vesting, tax-withheld shares on Form 4 - Stock Titan
Moderna (NASDAQ:MRNA) Vaccine Momentum Turns Heads - Kalkine Media
Moderna shares rise as investors continue to digest pipeline expansion and flu vaccine progress - Quiver Quantitative
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna stock hits 52-week high at 81.42 USD - Investing.com
17,700 Shares in Moderna, Inc. $MRNA Bought by Louisiana State Employees Retirement System - MarketBeat
Price to sales forward of Moderna, Inc. – NASDAQ:MRNA - TradingView
MRNA Stock Quote Price and Forecast - CNN
Moderna | History, Innovation, Challenges, & Facts - Encyclopedia Britannica
Jim Cramer Turns Bullish on Moderna After 150% Rally, Citing Cancer Pipeline and Flu Vaccine Momentum - finance.biggo.com
Jim Cramer Says “For the First Time in Ages, I Like Having a Position in Moderna” - Yahoo Finance
MRNAModerna Inc Latest SEC Filings - Finviz
Moderna Stock (MRNA) Opinions on mRNA Flu Vaccine Approval and Stock Surge - Quiver Quantitative
Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%. What Gives? - The Globe and Mail
Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026? - The Motley Fool
MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week? - Yahoo Finance
Jim Cramer turns bullish on health care stock after years of doubt - thestreet.com
Trump's Newly Disclosed Moderna Trades Preceded FDA Advisory Panel's Unanimous Backing of MRNA Flu Vaccine - Moomoo
Moderna (NASDAQ:MRNA) gains $2.9 billion as investors pile into flu push, beating 2025 revenue - TechStock²
Tesla, Rivian, Strategy, Moderna, Sandisk, Blue Owl, and More Stocks That Explain Today’s Market - Barron's
MRNA Stock Surges As Flu Win And CAR-T Hype Fuel Breakout - StocksToTrade
Trump’s Newly Disclosed Moderna Trades Preceded FDA Advisory Panel’s Unanimous Backing of mRNA Flu Vaccine - Quiver Quantitative
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.29%
0.99%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):